Directorate Change


 

TIDMYRK 
 
RNS Number : 4850U 
York Pharma plc 
25 June 2009 
 

 
 
25 June 2009 
 
 
 
 
York Pharma plc 
("York" or the "Company") 
 
 
 
Directorate change 
 
 
 
 
York today announces that it has mutually agreed terms for the departure of 
Terry Sadler, Founder and President from the Board. 
 
 
The Company announced yesterday that discussions with Uluru Inc on the proposed 
terms indicated in the announcement of 7 April 2009 had been terminated and the 
requirement for the Company to repay to Uluru the $1 million line of credit 
previously advanced by Uluru to York.  Mr Sadler will resign from the Board of 
Directors and leave the Company upon the repayment of the line of credit by 
York. 
 
 
As announced, York is now actively pursuing alternative funding facilities in 
order to repay the line of credit before 22 July 2009 and to meet its ongoing 
working capital requirements. 
 
 
Commenting on Mr Sadler's departure, Max Dyer-Bartlett, Chairman of the Company 
said "Terry achieved a tremendous amount in building the York business. He will 
leave the Board with our thanks for the effort he has put in for the past six 
years and for the support he has provided to the new team since their 
appointment in January this year". 
 
 
 
 
For more information please contact: 
 
 
+---------------------------------------+----------------------------+ 
| York Pharma plc                       | Tel: +44 (0) 1908 764020   | 
| Richard Anderson, Chief Executive     |                            | 
| Officer                               |                            | 
| Ian Miscampbell, Chief Financial      |                            | 
| Officer                               |                            | 
+---------------------------------------+----------------------------+ 
| Collins Stewart Europe Limited        | Tel: +44 (0) 207 523 8350  | 
| Hugh Field / Adam Cowen               |                            | 
+---------------------------------------+----------------------------+ 
| Financial Dynamics                    | Tel: +44 (0) 207 831 3113  | 
| Ben Brewerton / Emma Thompson         |                            | 
+---------------------------------------+----------------------------+ 
 
 
Collins Stewart Europe Limited, which is authorised and regulated in the United 
Kingdom by the Financial Services Authority, is acting as Nominated Advisor and 
broker to York Pharma plc and will not be responsible to anyone other than York 
Pharma plc for providing the protections afforded to clients of Collins Stewart 
Europe Limited nor for providing advice in connection with any other matter 
referred to herein. 
 
 
 
 
=-o-- 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 BOASEUSWISUSEDM

York Pharma (LSE:YRK)
過去株価チャート
から 5 2024 まで 6 2024